Emory Joins National HIV Prevention Trials Network, Begins New Clinical Trials
Emory University's HIV Clinical Trials Unit has been selected to join the NIH-sponsored HIV Prevention Trials Network (HPTN), a worldwide collaborative clinical trials group that develops and tests non-vaccine interventions to prevent HIV transmission. ACTSI investigator Carlos del Rio, chair of the Hubert Department of Global Health in the Rollins School of Public Health, is principal investigator at Emory for the HPTN trials. Emory researchers will receive a grant of $4.8 million over three years for participation. The Emory HIV Clinical Trials Unit soon will begin recruiting patients for its first two clinical studies in the HPTN. The HPTN focuses on four research areas for HIV prevention: antiretroviral therapies, behavioral interventions, STD control, and substance abuse. Through its new membership in the worldwide HIV Prevention Trials Network (HPTN), Emory physician/researchers in the Center for AIDS Research and the ACTSI-funded Emory Vaccine Center will add a new arm of potentially lifesaving research to their wide-ranging efforts to prevent and treat HIV and AIDS. Read more. . .